サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1791566

化学療法在宅サービスの世界市場

Chemotherapy At-Home Services

出版日
ページ情報
英文 179 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.50円
化学療法在宅サービスの世界市場
出版日: 2025年08月15日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 179 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

化学療法在宅サービスの世界市場は2030年までに28億米ドルに達する見込み

2024年に18億米ドルと推定される化学療法在宅サービスの世界市場は、2024～2030年の分析期間においてCAGR 7.7%で成長し、2030年には28億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである経口化学療法は、CAGR 8.8%を記録し、分析期間終了までに18億米ドルに達すると予測されます。輸液化学療法セグメントの成長率は、分析期間中CAGR 5.6％と推定されます。

米国市場は4億6,480万米ドルと推定、中国はCAGR7.4％で成長予測

米国の化学療法在宅サービス市場は、2024年に4億6,480万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに4億3,920万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは7.4%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ7.2％と6.4％と予測されています。欧州では、ドイツがCAGR約6.0%で成長すると予測されています。

世界の化学療法在宅サービス市場- 主要動向と促進要因のまとめ

がん治療の未来は病院の壁を超えるか？

患者中心の、利用しやすく柔軟ながん治療に対する需要の高まりは、従来の化学療法管理モデルを再定義し、化学療法在宅サービスを脚光を浴びています。ヘルスケアシステムが世界的に、がん治療のワークフローを最適化し、患者が病院環境にさらされる機会を減らす方法を模索している中、在宅化学療法は、特に低リスクの患者や維持療法を受けている患者にとって、説得力のある選択肢として浮上してきました。この動向は、ポータブル輸液技術や在宅モニタリングツールの進歩、そして分散型サービス提供をますますサポートするようになった腫瘍内科治療プロトコルの進化に後押しされ、勢いを増しています。病院やがんセンターは、専門の在宅ケア・プロバイダーと提携してハイブリッド・ケア・モデルを構築し、患者が快適な自宅で輸液を受けながら腫瘍内科医が監視を続けられるようにしています。在宅サービスは、地方や、移動が大きな負担となる免疫不全患者にとって特に有益であることが証明されつつあります。さらに、医療システムが入院患者の収容能力の制約や腫瘍科の症例数の増加に苦慮している中、臨床転帰を損なうことなく、重要でない化学療法レジメンを在宅環境に移行することで、輸液センターの負担を軽減しています。COVID-19の大流行は、このモデルの検証を加速させ、多くのパイロットプログラムや公的ヘルスケアシステムにおいて、その安全性、実現可能性、患者の満足度を証明しました。

在宅化学療法の安全性、モニタリング、提供は、技術によってどのように強化されているのでしょうか？

技術の進歩は、在宅化学療法サービスの拡張性と安全性を支える上で極めて重要な役割を果たしています。ポータブル輸液ポンプ、投与量制御送達システム、ウェアラブル患者モニタリングデバイス、スマート輸液キットは、現在、臨床施設の外で高精度のケアを可能にするために不可欠なものとなっています。遠隔患者モニタリング（RPM）、遠隔腫瘍学プラットフォーム、統合電子カルテ（EHR）などのデジタルツールにより、ケアチームは患者のバイタル、症状、アドヒアランスをリアルタイムで追跡することができます。このリモート接続は臨床リスクを軽減するだけでなく、合併症が発生した場合にタイムリーな介入を可能にし、ケアの継続性を確保します。ファーマコビジランス・ツールとリアルタイム分析は、副作用やコンプライアンス違反の兆候を早期に発見し、臨床的意思決定をさらにサポートします。安全な薬剤投与と現場での患者サポートのために、移動式看護ユニットや腫瘍学の訓練を受けた在宅ケアの専門家がデジタルツールを装備するようになってきています。クラウドベースの文書化プラットフォームの統合により、腫瘍内科医、薬剤師、在宅ヘルスケアチーム間の安全なコミュニケーションが確保され、臨床の分断が減少しています。さらに、コールドチェーンロジスティクスとプレフィルド輸液キットの進歩により、リスクの高い細胞毒性薬剤を非臨床環境で安全に保管、輸送、投与できるようになりました。これらの技術革新は、施設と在宅での化学療法とのギャップを埋め、分散型がん治療を実行可能で成長する現実にしています。

なぜ患者も支払者も在宅がん治療へのシフトを受け入れているのか？

化学療法在宅サービスの成長の主な原動力は、消費者行動と支払者のダイナミクスの変化です。今日のペイシェントジャーニーは、快適性、利便性、自律性を優先して治療を受ける傾向が強まっています。通院による心理的ストレス、院内感染のリスク、移動による疲労、待ち時間の長期化などは、従来の化学療法を行う上での大きな障害となっています。在宅での選択肢は、治療アドヒアランスと患者の幸福感を向上させるために不可欠な、コントロール感、感情的な快適さ、平常心を提供します。並行して、医療保険プロバイダーや政府出資のヘルスケアシステムは、在宅輸液サービスの費用対効果を認めています。入院、病床占有率、関連する運営経費を削減することで、治療の質を落とすことなく、患者一人当たりの治療費を大幅に下げることができます。その結果、特に慢性レジメンや緩和ケア患者に対する在宅腫瘍学的サービスに対応し、インセンティブを与えるような償還モデルが発展しつつあります。さらに、患者満足度スコアとQOL指標がヘルスケア提供システムの重要な業績評価指標となりつつあり、ケアモデルの多様化をさらに促しています。また、がん患者の高齢化と合併症の増加に伴い、移動のしやすさやアクセスのしやすさへの懸念も、在宅治療を患者、介護者、医療提供者のいずれにとっても魅力的なものにしています。

化学療法在宅サービス市場の急成長の原動力は？

化学療法在宅サービス市場の成長は、技術の進歩、患者中心のヘルスケアモデル、治療プロトコルの進化、体系的なヘルスケア再編に根ざしたいくつかの要因によって牽引されています。外来輸液デバイス、デジタルヘルスプラットフォーム、遠隔モニタリング技術の採用が増加し、分散型がん医療をサポートする強力な技術基盤が構築されました。同時に、より管理しやすい維持療法ベースのレジメンへとシフトするがん治療パラダイムの変化により、在宅化学療法が臨床的に実行可能な選択肢となりつつあります。がん罹患率の増加、特に高齢化社会におけるがん罹患率の増加は、利用しやすい非施設的な治療法に対する需要を拡大しています。患者のQOLを向上させ、病院への依存を減らすことがより重視されるようになり、臨床診療とヘルスケア政策の両方に影響を与えています。保険償還やバリュー・ベース・ケアの取り組みによる支払者の支援は、在宅サービスの市場導入を加速させています。在宅輸液サービス専門のプロバイダーや移動式がん看護チームの出現は、業務の拡張性をさらに促進しています。さらに、公的医療制度改革と資源最適化戦略により、分散型サービス提供を優先するハイブリッド・ケアモデルが制度化されつつあります。これらの要因が相まって、化学療法在宅サービスの成長のための肥沃な生態系が形成され、現代におけるがんケアの提供方法が再定義されつつあります。

セグメント

製品タイプ（経口化学療法、輸液化学療法）、がんタイプ（白血病、乳がん、大腸がん、直腸がん、子宮頸がん、肺がん、前立腺がん、卵巣がん）

調査対象企業の例

  • Advocate Health at Home
  • Amedisys
  • Bayada Home Health Care
  • BrightStar Care
  • Bupa Cromwell Hospital
  • Cancer Treatment Centers of America
  • ChemoAtHome
  • Clatterbridge Cancer Centre NHS Foundation Trust
  • Coram CVS Specialty Infusion Services
  • Healthcare at Home
  • Home Instead
  • Interim HealthCare
  • Kindred at Home
  • LHC Group
  • LloydsPharmacy Clinical Homecare
  • Option Care Health
  • Penn Medicine Cancer Care at Home
  • Sciensus
  • UnityPoint at Home
  • VITAS Healthcare

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP29924

Global Chemotherapy At-Home Services Market to Reach US$2.8 Billion by 2030

The global market for Chemotherapy At-Home Services estimated at US$1.8 Billion in the year 2024, is expected to reach US$2.8 Billion by 2030, growing at a CAGR of 7.7% over the analysis period 2024-2030. Oral Chemotherapy, one of the segments analyzed in the report, is expected to record a 8.8% CAGR and reach US$1.8 Billion by the end of the analysis period. Growth in the Infusion Chemotherapy segment is estimated at 5.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$464.8 Million While China is Forecast to Grow at 7.4% CAGR

The Chemotherapy At-Home Services market in the U.S. is estimated at US$464.8 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$439.2 Million by the year 2030 trailing a CAGR of 7.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.2% and 6.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.0% CAGR.

Global Chemotherapy At-Home Services Market - Key Trends & Drivers Summarized

Is the Future of Oncology Care Moving Beyond Hospital Walls?

The rising demand for patient-centric, accessible, and flexible cancer care is redefining traditional chemotherapy administration models, bringing chemotherapy at-home services into the spotlight. As healthcare systems globally seek ways to optimize oncology workflows and reduce patient exposure to hospital environments, at-home chemotherapy has emerged as a compelling alternative, particularly for low-risk patients and those undergoing maintenance treatments. The trend is gaining momentum, driven by advancements in portable infusion technologies, home-based monitoring tools, and evolving oncology care protocols that increasingly support decentralized service delivery. Hospitals and cancer centers are partnering with specialized home care providers to create hybrid care models, enabling oncologists to maintain oversight while patients receive infusions in the comfort of their homes. At-home services are proving especially beneficial in rural areas or for immunocompromised patients where travel poses significant burdens. Moreover, as health systems struggle with inpatient capacity constraints and growing oncology caseloads, shifting non-critical chemotherapy regimens to the home setting is reducing strain on infusion centers without compromising clinical outcomes. The COVID-19 pandemic accelerated the validation of this model, proving its safety, feasibility, and patient satisfaction levels across numerous pilot programs and public healthcare systems.

How Is Technology Enhancing Safety, Monitoring, and Delivery of Chemotherapy at Home?

Technological advancements have played a pivotal role in supporting the scalability and safety of at-home chemotherapy services. Portable infusion pumps, dose-controlled delivery systems, wearable patient monitoring devices, and smart infusion kits are now integral to enabling high-precision care outside clinical facilities. Digital tools such as remote patient monitoring (RPM), teleoncology platforms, and integrated electronic health records (EHR) allow care teams to track patient vitals, symptoms, and adherence in real time. This remote connectivity not only mitigates clinical risk but also enables timely intervention in case of complications, ensuring continuity of care. Pharmacovigilance tools and real-time analytics further support clinical decision-making by flagging early signs of adverse drug reactions or non-compliance. Mobile nursing units and oncology-trained homecare professionals are increasingly equipped with digital tools for safe drug administration and on-site patient support. The integration of cloud-based documentation platforms ensures secure communication between oncologists, pharmacists, and home healthcare teams, reducing clinical fragmentation. Additionally, advances in cold chain logistics and pre-filled infusion kits allow high-risk cytotoxic drugs to be safely stored, transported, and administered in non-clinical environments. These innovations collectively bridge the gap between institutional and home-based chemotherapy, making decentralized cancer care a viable and growing reality.

Why Are Patients and Payers Alike Embracing the Shift to Home-Based Oncology Services?

A key driving force behind the growth of chemotherapy at-home services is changing consumer behavior and payer dynamics. Patients today are increasingly prioritizing comfort, convenience, and autonomy in their treatment journeys. The psychological stress of hospital visits, risk of nosocomial infections, travel fatigue, and prolonged waiting times are major deterrents to conventional chemotherapy administration. At-home options offer a sense of control, emotional comfort, and normalcy, which are essential for improving treatment adherence and patient well-being. In parallel, health insurance providers and government-funded healthcare systems are recognizing the cost-effectiveness of home-based infusion services. Reducing hospital admissions, bed occupancy, and associated operational overheads significantly lowers the per-patient treatment cost without compromising quality of care. Consequently, reimbursement models are evolving to accommodate and incentivize home-based oncology services, especially for chronic regimens and palliative care patients. Additionally, patient satisfaction scores and quality-of-life metrics are becoming key performance indicators for healthcare delivery systems, further encouraging care model diversification. As the demographic of cancer patients becomes increasingly elderly and comorbid, mobility and accessibility concerns are also making home-based treatments more appealing to patients, caregivers, and providers alike.

What Is Driving the Rapid Growth in the Chemotherapy At-Home Services Market?

The growth in the chemotherapy at-home services market is driven by several factors rooted in technological progression, patient-centric healthcare models, evolving treatment protocols, and systemic healthcare restructuring. The increasing adoption of ambulatory infusion devices, digital health platforms, and remote monitoring technologies has created a strong technological foundation to support decentralized oncology care. Simultaneously, changing cancer treatment paradigms, with a shift toward more manageable, maintenance-based regimens, are making home-based chemotherapy a clinically viable option. Growing cancer prevalence, especially among aging populations, is expanding the demand pool for accessible, non-institutionalized treatment solutions. A broader emphasis on improving patient quality of life and reducing hospital dependency is influencing both clinical practice and healthcare policy. Payer support through insurance reimbursement and value-based care initiatives is accelerating the market uptake of at-home services. The emergence of specialized home infusion service providers and mobile oncology nursing teams is further fueling operational scalability. Moreover, public health system reforms and resource optimization strategies are institutionalizing hybrid care models that prioritize decentralized service delivery. Collectively, these factors are creating a fertile ecosystem for the growth of chemotherapy at-home services, redefining how cancer care is delivered in the modern era.

SCOPE OF STUDY:

The report analyzes the Chemotherapy At-Home Services market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Oral Chemotherapy, Infusion Chemotherapy); Cancer Type (Leukemia, Breast Cancer, Colon Cancer, Rectum Cancer, Cervix Uteri Cancer, Lung Cancer, Prostate Cancer, Ovarian Cancer)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 32 Featured) -

  • Advocate Health at Home
  • Amedisys
  • Bayada Home Health Care
  • BrightStar Care
  • Bupa Cromwell Hospital
  • Cancer Treatment Centers of America
  • ChemoAtHome
  • Clatterbridge Cancer Centre NHS Foundation Trust
  • Coram CVS Specialty Infusion Services
  • Healthcare at Home
  • Home Instead
  • Interim HealthCare
  • Kindred at Home
  • LHC Group
  • LloydsPharmacy Clinical Homecare
  • Option Care Health
  • Penn Medicine Cancer Care at Home
  • Sciensus
  • UnityPoint at Home
  • VITAS Healthcare

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Chemotherapy At-Home Services - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Preference for Patient-Centric Cancer Care Throws the Spotlight on At-Home Chemotherapy Services
    • Shift Toward Decentralized Healthcare Delivery Models Expands Addressable Market for Home-Based Oncology Services
    • Integration of Remote Monitoring Technologies and Teleoncology Drives Adoption of At-Home Infusion Solutions
    • Increasing Hospital Capacity Pressures and Staff Shortages Propel Growth in Alternate Site Cancer Care
    • Advancements in Portable Infusion Devices Strengthen the Business Case for Home-Based Chemotherapy Administration
    • Surge in Demand for Immunocompromised Patient Safety Accelerates Migration from Hospital to Home Settings
    • Growing Acceptance of Hybrid Care Models Generates Opportunities for Integrated Oncology Service Providers
    • Insurance Reimbursement Reforms and Value-Based Care Models Drive Wider Adoption of Chemotherapy At-Home Services
    • High Patient Satisfaction and Improved Quality of Life Metrics Sustain Growth Momentum in Home Infusion Programs
    • Expansion of Specialized Oncology Homecare Nursing Networks Spurs Market Scalability
    • Clinical Validation and Pilot Program Success Stories Strengthen Stakeholder Confidence in Home-Based Cancer Care Models
    • Rising Prevalence of Cancer in Aging Populations Creates Long-Term Demand for Accessible, Non-Hospital Treatments
    • Increasing Demand for Cost-Effective Treatment Pathways Drives Adoption in Public and Private Healthcare Systems
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Chemotherapy At-Home Services Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Chemotherapy At-Home Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Chemotherapy At-Home Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Chemotherapy At-Home Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Oral Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Oral Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Oral Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Infusion Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Infusion Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Infusion Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Ovarian Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Ovarian Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Ovarian Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Leukemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Leukemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Leukemia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Breast Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Colon Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Colon Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Colon Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Rectum Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Rectum Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Rectum Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Cervix Uteri Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Cervix Uteri Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Cervix Uteri Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Lung Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Prostate Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Prostate Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Prostate Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Chemotherapy At-Home Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 35: USA Recent Past, Current & Future Analysis for Chemotherapy At-Home Services by Product Type - Oral Chemotherapy and Infusion Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Chemotherapy At-Home Services by Product Type - Oral Chemotherapy and Infusion Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: USA 15-Year Perspective for Chemotherapy At-Home Services by Product Type - Percentage Breakdown of Value Sales for Oral Chemotherapy and Infusion Chemotherapy for the Years 2015, 2025 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Chemotherapy At-Home Services by Cancer Type - Ovarian Cancer, Leukemia, Breast Cancer, Colon Cancer, Rectum Cancer, Cervix Uteri Cancer, Lung Cancer and Prostate Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Chemotherapy At-Home Services by Cancer Type - Ovarian Cancer, Leukemia, Breast Cancer, Colon Cancer, Rectum Cancer, Cervix Uteri Cancer, Lung Cancer and Prostate Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: USA 15-Year Perspective for Chemotherapy At-Home Services by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Leukemia, Breast Cancer, Colon Cancer, Rectum Cancer, Cervix Uteri Cancer, Lung Cancer and Prostate Cancer for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Chemotherapy At-Home Services by Product Type - Oral Chemotherapy and Infusion Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Chemotherapy At-Home Services by Product Type - Oral Chemotherapy and Infusion Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: Canada 15-Year Perspective for Chemotherapy At-Home Services by Product Type - Percentage Breakdown of Value Sales for Oral Chemotherapy and Infusion Chemotherapy for the Years 2015, 2025 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Chemotherapy At-Home Services by Cancer Type - Ovarian Cancer, Leukemia, Breast Cancer, Colon Cancer, Rectum Cancer, Cervix Uteri Cancer, Lung Cancer and Prostate Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Chemotherapy At-Home Services by Cancer Type - Ovarian Cancer, Leukemia, Breast Cancer, Colon Cancer, Rectum Cancer, Cervix Uteri Cancer, Lung Cancer and Prostate Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: Canada 15-Year Perspective for Chemotherapy At-Home Services by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Leukemia, Breast Cancer, Colon Cancer, Rectum Cancer, Cervix Uteri Cancer, Lung Cancer and Prostate Cancer for the Years 2015, 2025 & 2030
  • JAPAN
    • Chemotherapy At-Home Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Chemotherapy At-Home Services by Product Type - Oral Chemotherapy and Infusion Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Chemotherapy At-Home Services by Product Type - Oral Chemotherapy and Infusion Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: Japan 15-Year Perspective for Chemotherapy At-Home Services by Product Type - Percentage Breakdown of Value Sales for Oral Chemotherapy and Infusion Chemotherapy for the Years 2015, 2025 & 2030
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Chemotherapy At-Home Services by Cancer Type - Ovarian Cancer, Leukemia, Breast Cancer, Colon Cancer, Rectum Cancer, Cervix Uteri Cancer, Lung Cancer and Prostate Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Chemotherapy At-Home Services by Cancer Type - Ovarian Cancer, Leukemia, Breast Cancer, Colon Cancer, Rectum Cancer, Cervix Uteri Cancer, Lung Cancer and Prostate Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: Japan 15-Year Perspective for Chemotherapy At-Home Services by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Leukemia, Breast Cancer, Colon Cancer, Rectum Cancer, Cervix Uteri Cancer, Lung Cancer and Prostate Cancer for the Years 2015, 2025 & 2030
  • CHINA
    • Chemotherapy At-Home Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 53: China Recent Past, Current & Future Analysis for Chemotherapy At-Home Services by Product Type - Oral Chemotherapy and Infusion Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: China Historic Review for Chemotherapy At-Home Services by Product Type - Oral Chemotherapy and Infusion Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: China 15-Year Perspective for Chemotherapy At-Home Services by Product Type - Percentage Breakdown of Value Sales for Oral Chemotherapy and Infusion Chemotherapy for the Years 2015, 2025 & 2030
    • TABLE 56: China Recent Past, Current & Future Analysis for Chemotherapy At-Home Services by Cancer Type - Ovarian Cancer, Leukemia, Breast Cancer, Colon Cancer, Rectum Cancer, Cervix Uteri Cancer, Lung Cancer and Prostate Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: China Historic Review for Chemotherapy At-Home Services by Cancer Type - Ovarian Cancer, Leukemia, Breast Cancer, Colon Cancer, Rectum Cancer, Cervix Uteri Cancer, Lung Cancer and Prostate Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: China 15-Year Perspective for Chemotherapy At-Home Services by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Leukemia, Breast Cancer, Colon Cancer, Rectum Cancer, Cervix Uteri Cancer, Lung Cancer and Prostate Cancer for the Years 2015, 2025 & 2030
  • EUROPE
    • Chemotherapy At-Home Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Chemotherapy At-Home Services by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Chemotherapy At-Home Services by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: Europe 15-Year Perspective for Chemotherapy At-Home Services by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Chemotherapy At-Home Services by Product Type - Oral Chemotherapy and Infusion Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for Chemotherapy At-Home Services by Product Type - Oral Chemotherapy and Infusion Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: Europe 15-Year Perspective for Chemotherapy At-Home Services by Product Type - Percentage Breakdown of Value Sales for Oral Chemotherapy and Infusion Chemotherapy for the Years 2015, 2025 & 2030
    • TABLE 65: Europe Recent Past, Current & Future Analysis for Chemotherapy At-Home Services by Cancer Type - Ovarian Cancer, Leukemia, Breast Cancer, Colon Cancer, Rectum Cancer, Cervix Uteri Cancer, Lung Cancer and Prostate Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for Chemotherapy At-Home Services by Cancer Type - Ovarian Cancer, Leukemia, Breast Cancer, Colon Cancer, Rectum Cancer, Cervix Uteri Cancer, Lung Cancer and Prostate Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: Europe 15-Year Perspective for Chemotherapy At-Home Services by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Leukemia, Breast Cancer, Colon Cancer, Rectum Cancer, Cervix Uteri Cancer, Lung Cancer and Prostate Cancer for the Years 2015, 2025 & 2030
  • FRANCE
    • Chemotherapy At-Home Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 68: France Recent Past, Current & Future Analysis for Chemotherapy At-Home Services by Product Type - Oral Chemotherapy and Infusion Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: France Historic Review for Chemotherapy At-Home Services by Product Type - Oral Chemotherapy and Infusion Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: France 15-Year Perspective for Chemotherapy At-Home Services by Product Type - Percentage Breakdown of Value Sales for Oral Chemotherapy and Infusion Chemotherapy for the Years 2015, 2025 & 2030
    • TABLE 71: France Recent Past, Current & Future Analysis for Chemotherapy At-Home Services by Cancer Type - Ovarian Cancer, Leukemia, Breast Cancer, Colon Cancer, Rectum Cancer, Cervix Uteri Cancer, Lung Cancer and Prostate Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: France Historic Review for Chemotherapy At-Home Services by Cancer Type - Ovarian Cancer, Leukemia, Breast Cancer, Colon Cancer, Rectum Cancer, Cervix Uteri Cancer, Lung Cancer and Prostate Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: France 15-Year Perspective for Chemotherapy At-Home Services by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Leukemia, Breast Cancer, Colon Cancer, Rectum Cancer, Cervix Uteri Cancer, Lung Cancer and Prostate Cancer for the Years 2015, 2025 & 2030
  • GERMANY
    • Chemotherapy At-Home Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 74: Germany Recent Past, Current & Future Analysis for Chemotherapy At-Home Services by Product Type - Oral Chemotherapy and Infusion Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Germany Historic Review for Chemotherapy At-Home Services by Product Type - Oral Chemotherapy and Infusion Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: Germany 15-Year Perspective for Chemotherapy At-Home Services by Product Type - Percentage Breakdown of Value Sales for Oral Chemotherapy and Infusion Chemotherapy for the Years 2015, 2025 & 2030
    • TABLE 77: Germany Recent Past, Current & Future Analysis for Chemotherapy At-Home Services by Cancer Type - Ovarian Cancer, Leukemia, Breast Cancer, Colon Cancer, Rectum Cancer, Cervix Uteri Cancer, Lung Cancer and Prostate Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Germany Historic Review for Chemotherapy At-Home Services by Cancer Type - Ovarian Cancer, Leukemia, Breast Cancer, Colon Cancer, Rectum Cancer, Cervix Uteri Cancer, Lung Cancer and Prostate Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: Germany 15-Year Perspective for Chemotherapy At-Home Services by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Leukemia, Breast Cancer, Colon Cancer, Rectum Cancer, Cervix Uteri Cancer, Lung Cancer and Prostate Cancer for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 80: Italy Recent Past, Current & Future Analysis for Chemotherapy At-Home Services by Product Type - Oral Chemotherapy and Infusion Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Italy Historic Review for Chemotherapy At-Home Services by Product Type - Oral Chemotherapy and Infusion Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: Italy 15-Year Perspective for Chemotherapy At-Home Services by Product Type - Percentage Breakdown of Value Sales for Oral Chemotherapy and Infusion Chemotherapy for the Years 2015, 2025 & 2030
    • TABLE 83: Italy Recent Past, Current & Future Analysis for Chemotherapy At-Home Services by Cancer Type - Ovarian Cancer, Leukemia, Breast Cancer, Colon Cancer, Rectum Cancer, Cervix Uteri Cancer, Lung Cancer and Prostate Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Italy Historic Review for Chemotherapy At-Home Services by Cancer Type - Ovarian Cancer, Leukemia, Breast Cancer, Colon Cancer, Rectum Cancer, Cervix Uteri Cancer, Lung Cancer and Prostate Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: Italy 15-Year Perspective for Chemotherapy At-Home Services by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Leukemia, Breast Cancer, Colon Cancer, Rectum Cancer, Cervix Uteri Cancer, Lung Cancer and Prostate Cancer for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Chemotherapy At-Home Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 86: UK Recent Past, Current & Future Analysis for Chemotherapy At-Home Services by Product Type - Oral Chemotherapy and Infusion Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: UK Historic Review for Chemotherapy At-Home Services by Product Type - Oral Chemotherapy and Infusion Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: UK 15-Year Perspective for Chemotherapy At-Home Services by Product Type - Percentage Breakdown of Value Sales for Oral Chemotherapy and Infusion Chemotherapy for the Years 2015, 2025 & 2030
    • TABLE 89: UK Recent Past, Current & Future Analysis for Chemotherapy At-Home Services by Cancer Type - Ovarian Cancer, Leukemia, Breast Cancer, Colon Cancer, Rectum Cancer, Cervix Uteri Cancer, Lung Cancer and Prostate Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: UK Historic Review for Chemotherapy At-Home Services by Cancer Type - Ovarian Cancer, Leukemia, Breast Cancer, Colon Cancer, Rectum Cancer, Cervix Uteri Cancer, Lung Cancer and Prostate Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: UK 15-Year Perspective for Chemotherapy At-Home Services by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Leukemia, Breast Cancer, Colon Cancer, Rectum Cancer, Cervix Uteri Cancer, Lung Cancer and Prostate Cancer for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Chemotherapy At-Home Services by Product Type - Oral Chemotherapy and Infusion Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Chemotherapy At-Home Services by Product Type - Oral Chemotherapy and Infusion Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: Rest of Europe 15-Year Perspective for Chemotherapy At-Home Services by Product Type - Percentage Breakdown of Value Sales for Oral Chemotherapy and Infusion Chemotherapy for the Years 2015, 2025 & 2030
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Chemotherapy At-Home Services by Cancer Type - Ovarian Cancer, Leukemia, Breast Cancer, Colon Cancer, Rectum Cancer, Cervix Uteri Cancer, Lung Cancer and Prostate Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Chemotherapy At-Home Services by Cancer Type - Ovarian Cancer, Leukemia, Breast Cancer, Colon Cancer, Rectum Cancer, Cervix Uteri Cancer, Lung Cancer and Prostate Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Rest of Europe 15-Year Perspective for Chemotherapy At-Home Services by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Leukemia, Breast Cancer, Colon Cancer, Rectum Cancer, Cervix Uteri Cancer, Lung Cancer and Prostate Cancer for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Chemotherapy At-Home Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Chemotherapy At-Home Services by Product Type - Oral Chemotherapy and Infusion Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Chemotherapy At-Home Services by Product Type - Oral Chemotherapy and Infusion Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 15-Year Perspective for Chemotherapy At-Home Services by Product Type - Percentage Breakdown of Value Sales for Oral Chemotherapy and Infusion Chemotherapy for the Years 2015, 2025 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Chemotherapy At-Home Services by Cancer Type - Ovarian Cancer, Leukemia, Breast Cancer, Colon Cancer, Rectum Cancer, Cervix Uteri Cancer, Lung Cancer and Prostate Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Chemotherapy At-Home Services by Cancer Type - Ovarian Cancer, Leukemia, Breast Cancer, Colon Cancer, Rectum Cancer, Cervix Uteri Cancer, Lung Cancer and Prostate Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 15-Year Perspective for Chemotherapy At-Home Services by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Leukemia, Breast Cancer, Colon Cancer, Rectum Cancer, Cervix Uteri Cancer, Lung Cancer and Prostate Cancer for the Years 2015, 2025 & 2030
  • REST OF WORLD
    • TABLE 104: Rest of World Recent Past, Current & Future Analysis for Chemotherapy At-Home Services by Product Type - Oral Chemotherapy and Infusion Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Rest of World Historic Review for Chemotherapy At-Home Services by Product Type - Oral Chemotherapy and Infusion Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: Rest of World 15-Year Perspective for Chemotherapy At-Home Services by Product Type - Percentage Breakdown of Value Sales for Oral Chemotherapy and Infusion Chemotherapy for the Years 2015, 2025 & 2030
    • TABLE 107: Rest of World Recent Past, Current & Future Analysis for Chemotherapy At-Home Services by Cancer Type - Ovarian Cancer, Leukemia, Breast Cancer, Colon Cancer, Rectum Cancer, Cervix Uteri Cancer, Lung Cancer and Prostate Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Rest of World Historic Review for Chemotherapy At-Home Services by Cancer Type - Ovarian Cancer, Leukemia, Breast Cancer, Colon Cancer, Rectum Cancer, Cervix Uteri Cancer, Lung Cancer and Prostate Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: Rest of World 15-Year Perspective for Chemotherapy At-Home Services by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Leukemia, Breast Cancer, Colon Cancer, Rectum Cancer, Cervix Uteri Cancer, Lung Cancer and Prostate Cancer for the Years 2015, 2025 & 2030

IV. COMPETITION